IL158593A0 - Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders - Google Patents
Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disordersInfo
- Publication number
- IL158593A0 IL158593A0 IL15859302A IL15859302A IL158593A0 IL 158593 A0 IL158593 A0 IL 158593A0 IL 15859302 A IL15859302 A IL 15859302A IL 15859302 A IL15859302 A IL 15859302A IL 158593 A0 IL158593 A0 IL 158593A0
- Authority
- IL
- Israel
- Prior art keywords
- cns
- obesity
- diabetes
- disorders
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0101660A SE0101660D0 (sv) | 2001-05-11 | 2001-05-11 | New compounds |
SE0101659A SE0101659D0 (sv) | 2001-05-11 | 2001-05-11 | New compounds |
US29413201P | 2001-05-29 | 2001-05-29 | |
US29410201P | 2001-05-29 | 2001-05-29 | |
SE0101958A SE0101958D0 (sv) | 2001-06-05 | 2001-06-05 | New compounds |
PCT/SE2002/000906 WO2002092585A1 (en) | 2001-05-11 | 2002-05-08 | Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL158593A0 true IL158593A0 (en) | 2004-05-12 |
Family
ID=27532724
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15859302A IL158593A0 (en) | 2001-05-11 | 2002-05-08 | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
IL158593A IL158593A (en) | 2001-05-11 | 2003-10-23 | Arylsulfonamide compounds, process for preparation thereof and pharmaceutical compositions for the treatment of obesity, type ii diabetes and cns-disorders |
IL194950A IL194950A0 (en) | 2001-05-11 | 2008-10-27 | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL158593A IL158593A (en) | 2001-05-11 | 2003-10-23 | Arylsulfonamide compounds, process for preparation thereof and pharmaceutical compositions for the treatment of obesity, type ii diabetes and cns-disorders |
IL194950A IL194950A0 (en) | 2001-05-11 | 2008-10-27 | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
Country Status (16)
Country | Link |
---|---|
US (4) | US7173035B2 (de) |
EP (1) | EP1406884A1 (de) |
JP (2) | JP4597480B2 (de) |
KR (1) | KR20090092832A (de) |
CN (1) | CN1329382C (de) |
AU (1) | AU2002303061B2 (de) |
BR (1) | BR0209558A (de) |
CA (1) | CA2443724C (de) |
EA (1) | EA009647B1 (de) |
HK (1) | HK1068335A1 (de) |
IL (3) | IL158593A0 (de) |
MX (1) | MXPA03010232A (de) |
NO (1) | NO326690B1 (de) |
NZ (1) | NZ528450A (de) |
PL (1) | PL366619A1 (de) |
WO (1) | WO2002092585A1 (de) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ528450A (en) * | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
US7718650B2 (en) * | 2001-05-11 | 2010-05-18 | Biovitrum Ab | Aryl sulfonamide compounds for treating obesity |
JP2004531319A (ja) * | 2001-05-29 | 2004-10-14 | ザ プロクター アンド ギャンブル カンパニー | スキンケアキット |
EA008476B1 (ru) | 2001-06-11 | 2007-06-29 | Биовитрум Аб | Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii |
US7456184B2 (en) | 2003-05-01 | 2008-11-25 | Palatin Technologies Inc. | Melanocortin receptor-specific compounds |
US7655658B2 (en) | 2001-08-10 | 2010-02-02 | Palatin Technologies, Inc. | Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds |
US7718802B2 (en) | 2001-08-10 | 2010-05-18 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
US7732451B2 (en) | 2001-08-10 | 2010-06-08 | Palatin Technologies, Inc. | Naphthalene-containing melanocortin receptor-specific small molecule |
AU2002331064B2 (en) | 2001-08-10 | 2007-08-23 | Palatin Technologies, Inc. | Peptidomimetics of biologically active metallopeptides |
US7354923B2 (en) * | 2001-08-10 | 2008-04-08 | Palatin Technologies, Inc. | Piperazine melanocortin-specific compounds |
ATE517626T1 (de) * | 2002-02-28 | 2011-08-15 | Univ Temple | Aminosubstituierte sulphonanilide und ihre derivate zur behandlung von proliferativen erkrankungen |
JP4754821B2 (ja) | 2002-06-20 | 2011-08-24 | プロキシマゲン・リミテッド | 肥満症、ii型糖尿病およびcns障害の治療に有用な新規化合物 |
MXPA04012914A (es) * | 2002-06-20 | 2005-03-31 | Biovitrum Ab | Nuevos compuestos utiles para el tratamiento de la obesidad, diabetes tipo ii y desordenes cns. |
GB0224830D0 (en) | 2002-10-24 | 2002-12-04 | Sterix Ltd | Compound |
SE0203753D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
SE0203754D0 (sv) * | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
EP2415760A3 (de) * | 2003-02-20 | 2012-02-22 | Encysive Pharmaceuticals, Inc. | CCR-9-Antagonisten |
US7968548B2 (en) | 2003-05-01 | 2011-06-28 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine compounds with diamine groups |
US7727990B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Melanocortin receptor-specific piperazine and keto-piperazine compounds |
US7727991B2 (en) | 2003-05-01 | 2010-06-01 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific single acyl piperazine compounds |
EA200600071A1 (ru) * | 2003-06-20 | 2006-08-25 | Арена Фармасьютикалз, Инк. | Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором |
US20050201965A1 (en) * | 2004-03-11 | 2005-09-15 | The Procter & Gamble Company | Personal cleansing compositions |
US7709484B1 (en) | 2004-04-19 | 2010-05-04 | Palatin Technologies, Inc. | Substituted melanocortin receptor-specific piperazine compounds |
CA2566387A1 (en) | 2004-05-12 | 2005-12-01 | Chemocentryx, Inc. | Aryl sulfonamides as chemokine receptor ccr9 antagonists |
EP1758882A4 (de) * | 2004-06-24 | 2008-01-23 | Incyte Corp | Amidverbindungen und ihre verwendung als arzneimittel |
EP1768954A4 (de) | 2004-06-24 | 2008-05-28 | Incyte Corp | 2-methylpropanamide und deren verwendung als pharmazeutika |
WO2006047302A1 (en) * | 2004-10-21 | 2006-05-04 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
AU2005316671A1 (en) * | 2004-12-13 | 2006-06-22 | Arena Pharmaceuticals, Inc. | N-biaryl and N-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5HT2C receptor useful for the treatment of disorders related thereto |
EP1676842A1 (de) * | 2004-12-30 | 2006-07-05 | Laboratorios Del Dr. Esteve, S.A. | Nitrosubstituierte Phenylpiperazinverbindungen, ihre Herstellung und Verwendung in Arzneimitteln |
EP1695971A1 (de) * | 2004-12-30 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Substituierte Phenylpiparazinverbindungen, deren Herstellung und Verwendung in Medikamenten |
NZ556761A (en) * | 2005-01-25 | 2011-04-29 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
CA2637766A1 (en) * | 2006-01-20 | 2007-11-08 | Smithkline Beecham Corporation | Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system |
BRPI0710177A2 (pt) * | 2006-04-19 | 2012-05-29 | Abbott Gmbh & Co Kg | arilsulfonas heterocìclicas adequadas para tratar distúrbios que respondem à modulação do receptor 5ht6 de serotonina |
US7834017B2 (en) | 2006-08-11 | 2010-11-16 | Palatin Technologies, Inc. | Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents |
WO2009137597A1 (en) * | 2008-05-06 | 2009-11-12 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT PRODUCTION OF sAPPβ AND Aβ AND USES THEREOF |
WO2010051064A1 (en) | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
US8343959B2 (en) | 2009-04-30 | 2013-01-01 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-HT6 receptor |
WO2010125134A1 (en) | 2009-04-30 | 2010-11-04 | Abbott Gmbh & Co. Kg | N-phenyl-(piperazinyl or homopiperazinyl)-benzenesulfonamide or benzenesulfonyl-phenyl-(piperazine or homopiperazine) compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
JP2012525356A (ja) * | 2009-04-30 | 2012-10-22 | アボット ゲーエムベーハー ウント カンパニー カーゲー | セロトニン5−ht6受容体の調節に応答する障害を治療するのに適したベンゼンスルホンアニリド化合物 |
EP2424844A1 (de) | 2009-04-30 | 2012-03-07 | Abbott GmbH & Co. KG | Benzolsulfonanilidverbindungen, die sich für die behandlung von erkrankungen eignen, die auf die modulation des serotonin-5-ht6-rezeptors ansprechen |
US9096558B2 (en) | 2010-07-09 | 2015-08-04 | Pfizer Limited | N-sulfonylbenzamide compounds |
WO2012059432A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | N-phenyl-(homo)piperazinyl-benzenesulfonyl or benzenesulfonamide compounds suitable for treating disorders that respond to the modulation of the 5-ht6 receptor |
WO2012059431A1 (en) | 2010-11-01 | 2012-05-10 | Abbott Gmbh & Co. Kg | Benzenesulfonyl or sulfonamide compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor |
TWI754702B (zh) * | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (氮雜)吲哚-和苯並呋喃-3-磺醯胺類 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2033597A5 (en) * | 1969-02-28 | 1970-12-04 | Ugine Kuhlmann | Green phthalocyanine metal dyes |
NL7310889A (de) * | 1972-08-12 | 1974-02-14 | ||
DE2239846A1 (de) * | 1972-08-12 | 1974-02-14 | Hoechst Ag | Basisch substituierte benzol-1,3disulfonamide und verfahren zu ihrer herstellung |
DE2334562A1 (de) * | 1973-07-07 | 1975-01-30 | Hoechst Ag | Basisch substituierte benzol-1,3-disulfonamide und verfahren zu ihrer herstellung |
DE2459394A1 (de) * | 1974-12-16 | 1976-06-24 | Hoechst Ag | Basisch substituierte benzol-1,3- disulfonamide und verfahren zu ihrer herstellung |
CA1331757C (en) * | 1988-02-29 | 1994-08-30 | Janssen Pharmaceutica Naamloze Vennootschap | 5-lipoxygenase inhibiting 4-(4-phenyl-1-piperazinyl)phenols |
DE19541146A1 (de) * | 1995-10-25 | 1997-04-30 | Schering Ag | Imidazolderivate und deren Verwendung als Stickstoffmonoxid-Synthase-Inhibitoren |
US5939451A (en) * | 1996-06-28 | 1999-08-17 | Hoffmann-La Roche Inc. | Use of sulfonamides |
SK20199A3 (en) * | 1996-08-15 | 2000-03-13 | Schering Corp | Ether muscarinic antagonists |
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
IL133870A0 (en) * | 1997-07-11 | 2001-04-30 | Smithkline Beecham Plc | Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation |
GB9801392D0 (en) * | 1998-01-22 | 1998-03-18 | Smithkline Beecham Plc | Novel compounds |
AU759255B2 (en) * | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6943159B1 (en) * | 1998-02-18 | 2005-09-13 | Neurosearch A/S | Compounds and their use as positive AMPA receptor modulators |
HUP0102622A3 (en) * | 1998-07-20 | 2002-12-28 | Merck Patent Gmbh | Biphenyl derivatives, process for producing them and pharmaceutical compositions containing them |
GB9818916D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
GB9818914D0 (en) * | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
EE200200095A (et) * | 1999-09-01 | 2003-04-15 | Aventis Pharma Deutschland Gmbh | Sulfonüülkarboksamiidi derivaadid, nende kasutamine, ravim ja nende valmistamismeetod |
DE19941559A1 (de) * | 1999-09-01 | 2001-03-15 | Aventis Pharma Gmbh | Verwendung von Bissulfonamiden zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Hyperlipidömie |
US6399617B1 (en) * | 2000-07-21 | 2002-06-04 | Biovitrum Ab | Use |
NZ528450A (en) | 2001-05-11 | 2006-02-24 | Biovitrum Ab | Novel, arylsulfonamide compounds for the treatment of obesity, type II diabetes and CNS-disorders |
-
2002
- 2002-05-08 NZ NZ528450A patent/NZ528450A/en unknown
- 2002-05-08 JP JP2002589470A patent/JP4597480B2/ja not_active Expired - Fee Related
- 2002-05-08 MX MXPA03010232A patent/MXPA03010232A/es not_active Application Discontinuation
- 2002-05-08 CN CNB028096142A patent/CN1329382C/zh not_active Expired - Fee Related
- 2002-05-08 AU AU2002303061A patent/AU2002303061B2/en not_active Ceased
- 2002-05-08 IL IL15859302A patent/IL158593A0/xx unknown
- 2002-05-08 EP EP02769640A patent/EP1406884A1/de not_active Withdrawn
- 2002-05-08 WO PCT/SE2002/000906 patent/WO2002092585A1/en active Application Filing
- 2002-05-08 EA EA200301232A patent/EA009647B1/ru not_active IP Right Cessation
- 2002-05-08 BR BR0209558-0A patent/BR0209558A/pt not_active IP Right Cessation
- 2002-05-08 CA CA002443724A patent/CA2443724C/en not_active Expired - Fee Related
- 2002-05-08 KR KR1020097014381A patent/KR20090092832A/ko not_active Application Discontinuation
- 2002-05-08 PL PL02366619A patent/PL366619A1/xx not_active Application Discontinuation
- 2002-05-10 US US10/143,335 patent/US7173035B2/en not_active Expired - Fee Related
- 2002-05-13 US US10/144,677 patent/US6969710B2/en not_active Expired - Fee Related
-
2003
- 2003-10-23 IL IL158593A patent/IL158593A/en not_active IP Right Cessation
- 2003-11-10 NO NO20034996A patent/NO326690B1/no not_active IP Right Cessation
-
2005
- 2005-01-13 HK HK05100327A patent/HK1068335A1/xx not_active IP Right Cessation
- 2005-08-30 US US11/214,523 patent/US7319097B2/en not_active Expired - Fee Related
- 2005-08-30 US US11/215,173 patent/US7566715B2/en not_active Expired - Fee Related
-
2008
- 2008-10-27 IL IL194950A patent/IL194950A0/en unknown
-
2010
- 2010-07-12 JP JP2010157953A patent/JP2011016801A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
IL194950A0 (en) | 2011-08-01 |
NO20034996D0 (no) | 2003-11-10 |
PL366619A1 (en) | 2005-02-07 |
US6969710B2 (en) | 2005-11-29 |
EA009647B1 (ru) | 2008-02-28 |
NO326690B1 (no) | 2009-01-26 |
WO2002092585A1 (en) | 2002-11-21 |
NZ528450A (en) | 2006-02-24 |
HK1068335A1 (en) | 2005-04-29 |
JP4597480B2 (ja) | 2010-12-15 |
BR0209558A (pt) | 2004-04-20 |
CA2443724C (en) | 2009-11-03 |
JP2004534755A (ja) | 2004-11-18 |
US20030149019A1 (en) | 2003-08-07 |
JP2011016801A (ja) | 2011-01-27 |
EA200301232A1 (ru) | 2004-04-29 |
US20050288275A1 (en) | 2005-12-29 |
CN1329382C (zh) | 2007-08-01 |
US7173035B2 (en) | 2007-02-06 |
KR20090092832A (ko) | 2009-09-01 |
CN1531531A (zh) | 2004-09-22 |
CA2443724A1 (en) | 2002-11-21 |
US7566715B2 (en) | 2009-07-28 |
US20060009446A1 (en) | 2006-01-12 |
IL158593A (en) | 2010-12-30 |
US7319097B2 (en) | 2008-01-15 |
AU2002303061B2 (en) | 2009-01-29 |
MXPA03010232A (es) | 2004-03-16 |
EP1406884A1 (de) | 2004-04-14 |
US20030149020A1 (en) | 2003-08-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL194950A0 (en) | Novel, arylsulfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders | |
HK1066790A1 (en) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes | |
AU2003281978A1 (en) | 2,5-diketopiperazines for the treatment of obesity | |
ZA200300434B (en) | Medicinal herbal compounds for the prevention and treatment of diabetes. | |
IL218909A0 (en) | Treatment of diabetes | |
AU2003299791A1 (en) | Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity | |
AP2004003002A0 (en) | azabicyclic-substituted fused-heteroaryl compoundsfor the treatment of disease. | |
IL165051A0 (en) | New compounds useful for the treatment of obesity,type II diabetes and cns disorders | |
PL370818A1 (en) | Dosage form for treatment of diabetes mellitus | |
HK1103928A1 (en) | 2-oxy-4h-3,1-benzoxazin-4-ones for treatment of obesity | |
IL159344A0 (en) | Quinuclidines-substituted-multicyclic-heteroaryls for the treatment of disease | |
MXPA03006936A (es) | Tratamiento de diabetes mellitus. | |
AU2002258428A1 (en) | Methods for the treatment of metabolic disorders, including obesity and diabetes | |
ZA200501288B (en) | Substituted 5-chroman-5-yl-ethylamine compounds and their use for the treatment of glaucoma. | |
AU2002330095A1 (en) | Flavonoids for treatment of diabetes | |
ZA200307475B (en) | Carbamate compounds for use in the treatment of pain. | |
AU2002236781A1 (en) | Treatment for snoring | |
EP1435962A4 (de) | Behandlung von diabetes vom typ 1 | |
GB0212790D0 (en) | Medicament for the treatment of diabetes | |
GB0103031D0 (en) | Novel treatment | |
AU2000272704A1 (en) | Use of compounds for the treatment of obesity | |
ZA200409489B (en) | Treatment for diabetes. | |
ZA200308097B (en) | Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes. | |
ZA200409030B (en) | New compounds useful for the treatment of obesity,type ii diabetes and CNS disorders. | |
GB0106468D0 (en) | Treatment of diabetes mellitus |